Our findings provide new insights into the molecular mechanisms of TUSC2-mediated tumor suppression, and suggest that the therapeutic activity of TUSC2 could extend the use of erlotinib to lung cancer patients with wildtype EGFR. Here, TUSC2 is linked to neoplasm.